Angiotech acquires Haemacure assets
This article was originally published in The Gray Sheet
Executive Summary
Angiotech Pharmaceuticals says it will pursue commercialization of Haemacure's human biomaterial product candidates, namely fibrin sealant and thrombin hemostat, after acquiring the firm's assets in a deal announced April 7. Potential applications include general and abdominal surgery, cardiothoracic and vascular surgery, gynecology and urology surgery and reconstructive and plastic surgery. The U.S. surgical sealing and hemostat market is estimated at $500 million-plus annually, according to Angiotech. The asset sale has been authorized under Haemacure's Chapter 11 bankruptcy court proceedings. Angiotech provided Haemacure with a $2.5 million bridge loan last June, and estimates that, at closing, "it will have funded approximately $1.5 million in additional transaction-related expenses.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.